SOURCE: 3D Signatures inc.

3D Signatures Inc.

January 04, 2017 07:00 ET

3D Signatures Common Shares Now Listed on the OTCQB and Frankfurt Stock Exchanges

Company Also Obtains DTC Eligibility for its Common Shares in the U.S.

WINNIPEG, MB--(Marketwired - January 04, 2017) - 3D Signatures Inc. (TSX VENTURE: DXD) (the "Company" or "3DS") is pleased to announce that its common shares have started trading on the OTCQB Venture Market (the "OTCQB") in the United States under the symbol "TDSGF" and on the Frankfurt Stock Exchange (the "FSE") in Germany under the symbol "3D0."

3DS also announced that it has secured Depository Trust Company ("DTC") eligibility for its common shares listed on the OTCQB. Securities that are eligible to be electronically cleared and settled through the DTC are considered "DTC eligible." This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors.

"The commencement of trading of our common shares on the OTCQB and the FSE mark another important step forward in 3DS' corporate development and are in parallel to anticipated international business development opportunities," commented the Company's CEO, Jason Flowerday. "We believe these listings, combined with securing DTC eligibility in the U.S., give 3DS exposure to a much broader international audience and more convenient platforms for U.S. and European investors to access and trade the Company's common shares."

The common shares of 3DS will continue to trade on the TSX Venture Exchange under its existing symbol "DXD."

About 3DS

3DS (TSX VENTURE: DXD) (OTCQB: TDSGF) (FRANKFURT: 3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer's disease. Depending on the desired application, the technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company's new website at http://www.3dsignatures.com.

Forward-Looking Information

This news release includes forward-looking statements that are subject to risks and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. All statements in this news release, other than statements of historical fact, are to be considered forward looking. In particular, the Company's statements concerning international business development opportunities as well as statements that the Company expects to benefit from the trading of its common shares on the OTCQB and the FSE and from its common shares becoming DTC eligible are forward-looking information. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: market demand; technological changes that could impact the Company's existing products or the Company's ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company's financial condition; the Company's ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. In addition, you should note that forward looking statements are made only as of the date of this news release and that we do not assume any obligation to update any forward-looking statements other than as required by law.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information